Relay Therapeutics (NASDAQ:RLAY) Insider Sells 18,895 Shares

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Donald Bergstrom sold 18,895 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total transaction of $143,979.90. Following the completion of the transaction, the insider directly owned 422,733 shares in the company, valued at approximately $3,221,225.46. The trade was a 4.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Relay Therapeutics Stock Performance

RLAY traded up $0.06 during trading on Thursday, hitting $7.71. The stock had a trading volume of 1,788,553 shares, compared to its average volume of 2,246,533. The stock has a 50 day simple moving average of $7.93 and a two-hundred day simple moving average of $5.93. Relay Therapeutics, Inc. has a twelve month low of $1.77 and a twelve month high of $9.04. The company has a market capitalization of $1.34 billion, a PE ratio of -4.41 and a beta of 1.55.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.04). On average, equities research analysts anticipate that Relay Therapeutics, Inc. will post -2.55 EPS for the current year.

Wall Street Analyst Weigh In

RLAY has been the topic of several recent analyst reports. Wells Fargo & Company upgraded shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $6.00 to $13.00 in a report on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. Finally, Oppenheimer upgraded shares of Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price objective for the company in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Relay Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $16.57.

Institutional Investors Weigh In On Relay Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FNY Investment Advisers LLC lifted its holdings in shares of Relay Therapeutics by 100.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock valued at $34,000 after buying an additional 5,000 shares during the period. Quinn Opportunity Partners LLC acquired a new position in Relay Therapeutics in the second quarter valued at approximately $35,000. May Hill Capital LLC purchased a new stake in Relay Therapeutics in the 2nd quarter worth approximately $38,000. Focus Partners Advisor Solutions LLC acquired a new stake in shares of Relay Therapeutics during the 2nd quarter worth approximately $39,000. Finally, Quadrant Capital Group LLC grew its stake in shares of Relay Therapeutics by 245.1% during the 2nd quarter. Quadrant Capital Group LLC now owns 11,791 shares of the company’s stock worth $41,000 after purchasing an additional 8,374 shares during the period. 96.98% of the stock is owned by institutional investors and hedge funds.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.